Primary Sjögren’s Syndrome Accompanied by Clinical Features of TAFRO Syndrome
Case Reports in Rheumatology · 17.09.2020 · 2020 · 1-7
DOI: 10.1155/2020/8872774 ↗Kurz gefasst
Fallbericht in der Zeitschrift Case Reports in Rheumatology, erschienen am 17.09.2020. Verfasst von Eiji Suzuki und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Ohta-Nishinouchi Hospital, 2-5-20, Nishinouchi, Koriyama City, Fukushima 963-8558, Japan. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Sjögren’s syndrome (SS) is associated with not only sicca symptoms but also various symptoms caused by extraglandular manifestation. The pathophysiology and comorbidities of TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly), which is thought to be a variant of multicentric Castleman’s disease, are not fully understood, and there are few data on the effectiveness of treatments. We report a patient of SS with TAFRO syndrome-like clinical features. A 52-year-old woman was admitted to our hospital because of abdominal distension. Laboratory data showed thrombocytopenia, and image findings showed massive ascites without evidence of malignant disease as confirmed by cytology. She was diagnosed with SS based on dysfunction of salivary secretion and positivity for anti-Ro/SS-A and La/SS-B antibodies, accompanied by clinical features of TAFRO syndrome based on the presence of anasarca and thrombocytopenia. High-dose corticosteroid for inflammation, anasarca, and thrombocytopenia was not effective. Cyclosporine was administered next, but anasarca and thrombocytopenia did not immediately improve until tolvaptan and eltrombopag were added. Although tolvaptan and eltrombopag were used for only a few months, the patient maintained a good condition with cyclosporine and low-dose prednisolone. In SS patients, activation of antigen-specific T lymphocytes is thought to be an important trigger that accelerates the immune response and is followed by hypercytokinemia. Therefore, using cyclosporine to suppress the activity of T lymphocytes is a reasonable treatment for SS accompanied with TAFRO syndrome-like pathophysiology. It might also be useful to administer tolvaptan or eltrombopag before the effects of immunosuppressants appear. If refractory inflammation with anasarca, thrombocytopenia, or lymphadenopathy is observed in an SS patient, complications with TAFRO syndrome-like pathophysiology should be considered.
Autor:innen und Institutionen
- Department of Rheumatology, Ohta-Nishinouchi Hospital, 2-5-20, Nishinouchi, Koriyama City, Fukushima 963-8558, Japan.
- Department of Hematology, Ohta-Nishinouchi Hospital, 2-5-20, Nishinouchi, Koriyama City, Fukushima 963-8558, Japan.
- Department of Rheumatology, Fukushima Medical University School of Medicine, 1, Hikarigaoka, Fukushima City, Fukushima 960-1295, Japan.
ORCID-Profile: Eiji Suzuki
Zitieren
APA
Suzuki, E., Ichimura, T., Kimura, S., Kanno, T., & Migita, K. (2020). Primary Sjögren’s Syndrome Accompanied by Clinical Features of TAFRO Syndrome. Case Reports in Rheumatology, 2020, 1-7. https://doi.org/10.1155/2020/8872774
Vancouver
Suzuki E, Ichimura T, Kimura S, Kanno T, Migita K. Primary Sjögren’s Syndrome Accompanied by Clinical Features of TAFRO Syndrome. Case Reports in Rheumatology. 2020;2020:1-7. doi:10.1155/2020/8872774
BibTeX
@article{Suzuki2020,
author = {Suzuki, Eiji and Ichimura, Takuya and Kimura, Satoru and Kanno, Takashi and Migita, Kiyoshi},
title = {Primary Sjögren’s Syndrome Accompanied by Clinical Features of TAFRO Syndrome},
journal = {Case Reports in Rheumatology},
year = {2020},
volume = {2020},
pages = {1--7},
doi = {10.1155/2020/8872774}
}
EUVIMED